Literature DB >> 2051022

Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor.

A M Lamas1, O G Leon, R P Schleimer.   

Abstract

The role of the eosinophil as an active proinflammatory cell in asthma and other allergic disorders has been well established. Glucocorticosteroids have long been used therapeutically as antiinflammatory agents in a variety of disease states where eosinophilia is a prominent feature. Although glucocorticoids are known to reduce tissue and circulating eosinophil numbers, the mechanisms by which they do so have not been clearly elucidated. Culture of eosinophils in vascular endothelial cell supernatants (VEC SUP) induces phenotypic and functional changes and prolongs the survival of the eosinophils. The survival-promoting activity in VEC SUP was shown to be granulocyte-macrophage CSF (GM-CSF) by neutralization with specific antibody. The potent glucocorticosteroid, dexamethasone (DEX), inhibited the prolongation of eosinophil survival caused by culture in either VEC SUP or human rGM-CSF. DEX (10(-6) M) exerted a direct survival-inhibitory effect on the eosinophil by the 4th day in culture in VEC SUP. This survival-inhibitory effect was dependent on the concentration of DEX (10(-10)-10(-6) M). Other glucocorticoids, including prednisolone (10(-7), 10(-6) M) and hydrocortisone (10(-7), 10(-6) M) also inhibited survival. The rank order of potency of the steroids indicates that this effect is mediated by a glucocorticoid receptor. This conclusion is supported by the failure of the sex steroids testosterone (10(-8)-10(-6) M) or beta-estradiol (10(-6) M) to inhibit eosinophil survival in the presence of VEC SUP. The effect of glucocorticoids on eosinophils is not a simple direct toxic effect because it was reversed by higher concentrations of GM-CSF. DEX shifted the GM-CSF dose-response curve for survival approximately fivefold to the right. GM-CSF induced a shift in eosinophil buoyant density which was partially blocked by DEX. These results suggest that glucocorticoids may inhibit elements of cytokine "priming" of eosinophils and that the eosinophilopenic effects of glucocorticoids may result in part from a direct effect on the eosinophil within a regulatory system involving cytokines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2051022

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease.

Authors:  Whitney W Stevens; Christopher J Ocampo; Sergejs Berdnikovs; Masafumi Sakashita; Mahboobeh Mahdavinia; Lydia Suh; Tetsuji Takabayashi; James E Norton; Kathryn E Hulse; David B Conley; Rakesh K Chandra; Bruce K Tan; Anju T Peters; Leslie C Grammer; Atsushi Kato; Kathleen E Harris; Roderick G Carter; Shigeharu Fujieda; Robert C Kern; Robert P Schleimer
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

Review 2.  An overview of glucocorticoid anti-inflammatory actions.

Authors:  R P Schleimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils.

Authors:  M P Hallsworth; T M Litchfield; T H Lee
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

4.  Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma.

Authors:  A Jatakanon; S Kharitonov; S Lim; P J Barnes
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

5.  Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD.

Authors:  S Saha; C Doe; V Mistry; S Siddiqui; D Parker; M Sleeman; E S Cohen; C E Brightling
Journal:  Thorax       Date:  2009-02-12       Impact factor: 9.139

6.  TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice.

Authors:  Laura McKinley; John F Alcorn; Alanna Peterson; Rachel B Dupont; Shernaaz Kapadia; Alison Logar; Adam Henry; Charles G Irvin; Jon D Piganelli; Anuradha Ray; Jay K Kolls
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

7.  Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium.

Authors:  E Her; J Frazer; K F Austen; W F Owen
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

8.  Cyclosporin A increases the pulmonary eosinophilia induced by inhaled Aspergillus antigen in mice.

Authors:  J M Wang; M Denis; M Fournier; M Laviolette
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Interleukin-3-induced up-regulation of CR3 expression on human eosinophils is inhibited by dexamethasone.

Authors:  A Hartnell; A B Kay; A J Wardlaw
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

10.  Glucocorticoids increase adipocytes in muscle by affecting IL-4 regulated FAP activity.

Authors:  Yanjun Dong; Kleiton Augusto Santos Silva; Yanlan Dong; Liping Zhang
Journal:  FASEB J       Date:  2014-06-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.